RTN4

Across TCGA pan-cancer cohorts, RTN4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RTN4 data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RTN4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RTN4 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where RTN4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.641	0.865	<.001	65	view →
LUAD	OS	Median	All	0.737	1.000	.001	36	view →
LSCC	OS	Quartile	All	0.618	0.920	.001	19	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	6	view →
UCEC	DFS	Tertile	All	0.815	1.000	.004	4	view →
GBM	DFS	Tertile	All	0.853	0.689	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RTN4–PDAC (DFS)

Open the PDAC breakdown →